Cardiovascular Inflammation Reduction Trial (CIRT)

A Randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate )LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome

November 22, 2017

  • Clinical Trial Information

    Trial Contact: DuPont, Ashley

    Trial Phone: 321.841.1505

  • IRB No: 13.147.09

    Protocol Abbrev: CIRT

    Principal Investigator: Sundeep Mediratta, MD

    Sub Investigators: Kasi, Vijaykumar MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: Version 1.7

    Treatment: Low-dose Methotrexate and Folic Acid

    Applicable Disease Sites: Diabetes, CAD, MI, Metabolic Syndrome

    Therapies Involved: Medication ID: NCT01594333

  • Objective

    Investigate whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages.

  • Key Eligibility

    MI or dual vessel coronary Artery disease and diabetes/metabolic syndrome